Distribution of CTLA-4 polymorphisms in allergic asthma

International Archives of Allergy and Immunology

Volumn 141, Issue 3, 2006, Pages 223-229

  Jasek, Monika ^a   Łuszczek, Wioleta ^a   Obojski, Andrzej ^b   Winiarska, Beata ^a   Hałubek, Katarzyna ^a   Nowak, Izabela ^a   Mańczak, Maria ^a   Wiśniewski, Andrzej ^a   Pawlik, Andrzej ^c   Jonkisz, Anna ^b   Lebioda, Arleta ^b   Majorczyk, Edyta ^a   Dobosz, Tadeusz ^b   Kuśnierczyk, Piotr ^a,d  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c POMERANIAN MEDICAL UNIVERSITY   (Poland)

^d University of Jan D ugosz   (Poland)

Author keywords

Allergic asthma; CTLA 4 gene; Polymorphisms

Indexed keywords

ADENINE; CYTOSINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GUANINE; THYMINE;

ALLERGIC ASTHMA; ARTICLE; CAUCASIAN; CHROMOSOME 2Q; CONTROLLED STUDY; CTLA 4 GENE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MICROSATELLITE MARKER; PHENOTYPE; POLAND; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE ACTIVATION;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; ASTHMA; GENE FREQUENCY; HUMANS; HYPERSENSITIVITY; IMMUNOSUPPRESSIVE AGENTS; POLAND; POLYMORPHISM, GENETIC;

EID: 33750158337     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000095292     Document Type: Article

References (56)

1. Kristiansen OP, Larsen ZM, Pociot F: CTLA-4 in autoimmune diseases - a general susceptibility gene to autoimmunity? Genes Immun 2000;1:170-184.
2. Egen JG, Kuhns MS, Allison JP: CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002;3:611-618.
3. Saito T, Yamasaki S: Negative feedback of T cell activation through inhibitory adapters and costimulatory receptors. Immunol Rev 2003;192:143-160.
4. Riley JL, June CH: The CD28 family: a T cell rheostat for therapeutic control of T-cell activation. Blood 2005;105:13-21.
5. Ueda H, Howson JM, Esposito L, Reward J, Snook H, Chamberlain G, Rainbow DB, Hunter KM, Smith AN, Di Genova G, Herr MH, Dahlman I, Payne F, Smyth D, Lowe C, Twells RC, Howlett S, Healy B, Nutland S, Rance HE, Everett V, Smink LJ, Lam AC, Cordell HJ, Walker NM, Bordin C, Hulme J, Motzo C, Cucca F, Hess JF, Metzker ML, Rogers J, Gregory S, Allahabadia A, Nithiyananthan R, Tuomilehto-Wolf E, Tuomilehto J, Bingley P, Gillespie KM, Undlien DE, Ronningen KS, Guja C, Ionescu-Tirgoviste C, Savage DA, Maxwell AP, Carson DJ, Patterson CC, Franklyn JA, Clayton DG, Peterson LB, Wicker LS, Todd JA, Gough SC: Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003;423:506-511.
6. Braun J, Donner H, Siegmund T, Walfish PG, Usadel KH, Badenhoop K: CTLA-4 promoter variants in patients with Graves' disease and Hashimoto's thyroiditis. Tissue Antigens 1998;51:563-566.
7. Vaidya B, Imrie H, Perros P, Young ET, Kelly WF, Carr D, Large DM, Toft AD, McCarthy MI, Kendall-Taylor P, Pearce SH: The cytotoxic T lymphocyte antigen-4 is a major Graves' disease locus. Hum Mol Genet 1999;8:1195-1199.
8. Kouki T, Sawai Y, Gardine CA, Fisfalen ME, Alegre ML, DeGroot LJ: CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol 2000;165:6606-6611.
9. Tomer Y, Greenberg DA, Barbesino G, Concepcion E, Davies TF: CTLA-4 and not CD28 is a susceptibility gene for thyroid autoantibody production. J Clin Endocrinol Metab 2001;86:1687-1693.
10. Van der Auwera BJ, Vandewalle CL, Schuit FC, Winnock F, De Leeuw IH, Van Imschoot S, Lamberigts G, Gorus FK: CTLA-4 gene polymorphism confers susceptibility to insulin-dependent diabetes mellitus (IDDM) independently from age and from other genetic or immune disease markers. The Belgian Diabetes Registry. Clin Exp Immunol 1997;110:98-103.
11. McCormack RM, Maxwell AP, Carson D, Patterson CC, Bingham A, Savage DA: Possible association between CTLA4 DNA polymorphisms and early onset type 1 diabetes in a UK population. Genes Immun 2001;2:233-235.
12. Harbo HF, Gulowsen CE, Vartdal F, Spurkland A: CTLA4 promoter and exon 1 dimorphisms in multiple sclerosis. Tissue Antigens 1999;53:106-110.
13. Suppiah V, Alloza I, Heggarty S, Goris A, Dubois B, Carton H, Vandenbroeck K: The CTLA4 +49 A/G*G-CT60*G haplotype is associated with susceptibility to multiple sclerosis in Flanders. J Neuroimmunol 2005;164:148-53.
14. Kantarci OH, Hebrink DD, Achenbach SJ, Atkinson EJ, Waliszewska A, Buckle G, McMurray CT, de Andrade M, Hafler DA, Weinshenker BG: CTLA4 is associated with susceptibility to multiple sclerosis. J Neuroimmunol 2003;134:133-141.
15. Naluai AT, Nilsson S, Samuelsson L, Gudjonsdottir AH, Ascher H, Ek J, Hallberg B, Kristiansson B, Martinsson T, Nerman O, Sollid LM, Wahlstrom J: The CTLA4/CD28 gene region on chromosome 2q33 confers susceptibility to celiac disease in a way possibly distinct from that of type 1 diabetes and other chronic inflammatory disorders. Tissue Antigens 2000;56:350-355.
16. Popat S, Hearle N, Hogberg L, Braegger CP, O'Donoghue D, Falth-Magnusson K, Holmes GK, Howdle PD, Jenkins H, Johnston S, Kennedy NP, Kumar PJ, Logan RF, Marsh MN, Mulder CJ, Torinsson Naluai A, Sjoberg K, Stenhammar L, Walters JR, Jewell DP, Houlston RS: Variation in the CTLA4/CD28 gene region confers an increased risk of coeliac disease. Ann Hum Genet 2002;66:125-137.
17. Djilali-Saiah I, Schmitz J, Harfouch-Hammoud E, Mougenot JF, Bach JF, Caillat-Zucman S: CTLA-4 gene polymorphism is associated with predisposition to coeliac disease. Gut 1998;43:187-189.
18. Schmidt-Weber CB, Blaser K: T-cell tolerance in allergic response. Allergy 2002;57:762-768.
19. Novak N, Allam J-P, Betten H, Haberstok J, Bieber T: The role of antigen presenting cells at distinct anatomic sites: they accelerate and they slow down allergies. Allergy 2004;59:5-14.
20. Daniels SE, Bhattacharrya S, James A, Leaves NI, Young A, Hill MR, Faux JA, Ryan GF, le Souef PN, Lathrop GM, Musk AW, Cookson WO: A genome-wide search for quantitative trait loci underlying asthma. Nature 1996;383:247-250.
21. Collaborative Study on the Genetics of Asthma: A genome-wide search for asthma susceptibility loci in ethnically diverse populations. Nat Genet 1997;15:389-392.
22. Wjst M, Fischer G, Immervoll T, Jung M, Saar K, Rueschendorf F, Reis A, Ulbrecht M, Gomolka M, Weiss EH, Jaeger L, Nickel R, Richter K, Kjellman NI, Griese M, von Berg A, Gappa M, Riedel F, Boehle M, van Koningsbruggen S, Schoberth P, Szczepanski R, Dorsch W, Silbermann M, Wichmann HE, et al. A genome-wide search for linkage to asthma. German Asthma Genetics Group. Genomics 1999;58:1-8.
23. Dizier MH, Besse-Schmittler C, Guilloud-Bataille M, Annesi-Maesano I, Boussaha M, Bousquet J, Charpin D, Degioanni A, Gormand F, Grimfeld A, Hochez J, Hyne G, Lockhart A, Luillier-Lacombe M, Matran R, Meunier F, Neukirch F, Pacheco Y, Parent V, Paty E, Pin I, Pison C, Scheinmann P, Thobie N, Vervloet D, Kauffmann F, Feingold J, Lathrop M, Demenais F: Genome screen for asthma and related phenotypes in the French EGEA study. Am J Respir Crit Care Med 2000;162:1812-1818.
24. Hoffjan S, Ober C: Present status on the genetic studies of asthma. Curr Opin Immunol 2002;14:709-717.
25. Pioli C, Gatta L, Ubaldi V, Doria G: Inhibition of IgG1 and IgE production by stimulation of the B cell CTL A-4 receptor. J Immunol 2000;165:5530-5536.
26. Howard TD, Postma DS, Hawkins GA, Koppelman GH, Zheng SL, Wysong AK, Xu J, Meyers DA, Bleecker ER: Fine mapping of an IgE-controlling gene on chromosome 2q: Analysis of CTLA4 and CD28. J Allergy Clin Immunol 2002;110:743-751.
27. Heinzmann A, Plesnar C, Kuehr J, Forster J, Deichmann KA: Common polymorphisms in the CTLA-4 and CD28 genes at 2q33 are not associated with asthma or atopy. Eur J Immunogenet 2000;27:57-61.
28. Hizawa N, Yamaguchi E, Jinushi E, Konno S, Kawakami Y, Nishimura M: Increased total serum IgE levels in patients with asthma and promoter polymorphisms at CTLA4 and FCER1B. J Allergy Clin Immunol 2001;108:74-79.
29. NHLBI/WHO Workshop Report: Global Strategy for Asthma Management and Prevention. NIH Publication No. 02-3659, February 2002.
30. Dreborg S, Backman A, Basomba A, Bousquet J, Digies P, Malling HI: Skin tests used in type I allergy testing. Position paper prepared by the Subcommittee on Skin Tests of the EAACI. Allergy 1989;44(suppl 10):1-59.
31. Dariavach P, Mattei MG, Golstein P, Lefranc MP: Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains. Eur J Immunol 1988;18:1901-1905.
32. Polymeropoulos MH, Xiao H, Rath DS, Merril CR: Dinucleotide repeat polymorphism at the human CTLA4 gene. Nucleic Acids Res 1991;19:4018.
33. Shi YY, He L: SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 2005;15:97-98.
34. H2 paradigm. J Allergy Clin Immunol 2004;114:280-287.
35. Nakao F, Ihara K, Ahmed S, Sasaki Y, Kusuhara K, Takabayashi A, Nishima S, Hara T: Lack of association between CD28/CTLA-4 gene polymorphisms and atopic asthma in the Japanese population. Exp Clin Immunogenet 2000;17:179-184.
36. Lee SY, Lee YH, Shin C, Shim JJ, Kang KH, Yoo SH, In KH: Association of asthma severity and bronchial hyperresponsiveness with a polymorphism in the cytotoxic T-lymphocyte antigen-4 gene. Chest 2002;122:171-176.
37. Yang KD, Liu CA, Chang JC, Chuang H, Ou CY, Hsu TY, Wang CL: Polymorphism of the immune-braking gene CTLA-4 (+49) involved in gender discrepancy of serum total IgE levels and allergic diseases. Clin Exp Allergy 2004;34:32-37.
38. Martin-Pagola A, Perez de Nanclares G, Vitoria JC, Bilbao JR, Ortiz L, Zubillaga P, Castano L: No association of CTLA4 gene with celiac disease in the Basque population. J Pediatr Gastroenterol Nutr 2003;37:142-145.
39. Park YJ, Chung HK, Park DJ, Kim WB, Kim SW, Koh JJ, Cho BY: Polymorphism in the promoter and exon 1 of the cytotoxic T lymphocyte antigen-4 gene associated with autoimmune thyroid disease in Koreans. Thyroid 2000;10:453-459.
40. Bednarczuk T, Hiromatsu Y, Fukutani T, Jazdzewski K, Miskiewicz P, Osikowska M, Nauman J: Association of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) gene polymorphism and non-genetic factors with Graves' ophthalmopathy in European and Japanese populations. Eur J Endocrinol 2003;148:13-18.
41. Hudson LL, Rocca K, Song YW, Pandey JP: CTLA-4 gene polymorphisms in systemic lupus erythematosus: a highly significant association with a determinant in the promoter region. Hum Genet 2002;111:452-455.
42. Ahmed S, Ihara K, Kanemitsu S, Nakashima H, Otsuka T, Tsuzaka K, Takeuchi T, Hara T: Association of CTLA-4 but not CD28 gene polymorphisms with systemic lupus erythematosus in the Japanese population. Rheumatology (Oxford) 2001;40:662-667.
43. Rodriguez MR, Nunez-Roldan A, Aguilar AF, Valenzuela A, Garcia A, Gonzalez-Escribano FM: Association of the CTLA4 3′ untranslated region polymorphism with the susceptibility to rheumatoid arthritis. Hum Immunol 2002;63:76-81.
44. Heward JM, Allahabadia A, Carr-Smith J, Daykin J, Cockram CS, Gordon C, Barnett AH, Franklyn JA, Gough SC: No evidence for allelic association of a human CTLA-4 promoter polymorphism with autoimmune thyroid disease in either population-based case-control or family-based studies. Clin Endocrinol (Oxf) 1998;49:331-334.
45. Heward J, Gordon C, Allahabadia A, Barnett AH, Franklyn JA, Gough SC: The A-G polymorphism in exon 1 of the CTLA-4 gene is not associated with systemic lupus erythematosus. Ann Rheum Dis 1999;58:193-195.
46. Lee YJ, Lo FS, Shu SG, Wang CH, Huang CY, Liu HF, Wu CC, Yang TY, Chang JG: The promoter region of the CTLA4 gene is associated with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2002;14:383-388.
47. Barton A, Jury F, Eyre S, Bowes J, Hinks A, Ward D, Worthington J: Haplotype analysis in simplex families and novel analytic approaches in a case-control cohort reveal no evidence of association of the CTLA-4 gene with rheumatoid arthritis. Arthritis Rheum 2004;50:748-752.
48. Suppiah V, Alloza I, Heggarty S, Dubois B, Carton H, Antiguedad A, Mendibe M, McDonnel G, Droogan A, Hawkins S, Graham C, Vandenbroek K: Polymorphisms in the interleukin-4 and IL-4 receptor genes and multiple sclerosis: a study in Spanish-Basque, Northern Irish and Belgian populations. Int J Immunogenet 2005;32:383-388.
49. Magistrelli G, Jeannin P, Herbault N, Benoit De Cognac A, Gauchat JF, Bonnefoy JY, Delneste Y: A soluble form of CTLA-4 generated by alternative splicing is expressed by non-stimulated human T cells. Eur J Immunol 1999;29:3596-3602.
50. Oaks MK, Hallett KM: Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease. J Immunol 2000;164:5015-5018.
51. Wang XB, Kakoulidou M, Giscombe R, Qiu Q, Huang DR, Pirskanen R, Lefvert AK: Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence. J Neuroimmunol 2002;130;224-232.
52. Sato S, Fujimoto M, Hasegawa M, Komura K, Yanaba K, Hayakawa I, Matsuhita T, Takehara K: Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis. Rheumatology (Oxford) 2004;43:1261-1266.
53. Shi HZ, Mo XY, Zhong XN: Soluble CTLA-4 in sera of patients with bronchial asthma. J Asthma 2005;42:133-139.
54. Wong CK, Lun SWM, Ko FWS, Ip WK, Hui DSC, Lam CWK: Increased expression of plasma and cell surface co-stimulatory molecules CTLA-4, CD28 and CD86 in adult patients with allergic asthma. Clin Exp Immunol 2005;141:122-129.
55. Purohit S, Podolsky R, Collins C, Zhang W, Schatz D, Muir A, Hopkins D, Huang Y-H, She J-X: Lack of correlation between the levels of soluble cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and the CT-60 genotypes. J Autoimmune Dis 2005;2:8.
56. Holopainen PM, Partanen JA: Technical note: Linkage disequilibrium and disease-associated CTLA4 gene polymorphisms. J Immunol 2001;167:2457-2458.